



Humanized Drug Target Models for Immunotherapy Evaluation



A JSR Life Sciences Company

QUICKFACT

V1.0


Discover the benefits that unique humanized target models featuring functional immune systems bring to immunotherapy drug development programs.

Humanized drug target models models allow the rapid evaluation of human-specific biological therapies *in vivo*, with:

- Humanized genetically engineered mouse models with stable humanized drug target expression, including PD-1, PD-L1, and CTLA-4
- Syngeneic tumor cells with stable humanized ligand expression, e.g. PD-L1
- Key checkpoint target platforms developed, including double knock-in models for combination ICI assessment, with many more under development

Choose humanized drug target models to:

- Interrogate the effectiveness of human-specific checkpoint inhibitors alone, or in combination with therapeutics potentiating the tumor immune microenvironment
- Evaluate your immunotherapies within a competent murine immune system featuring relevant human-specific targets
- Combine mouse and cell models for a fully humanized receptor-ligand complex
- Assess target engagement and pharmacodynamics of your immuno-oncology agents



Get in touch



US: +1 858 622 2900
UK: +44 (0)1530 234871

busdev@crownbio.com
www.crownbio.com

